ILMN Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 1066 min ago

@ $104.68

Išleistas: 28 birž. 2024 @ 21:02

Grąža: -0.29%

Ankstesnis signalas: birž. 28 - 18:58

Ankstesnis signalas: Pardavimas

Grąža: -1.25 %

Live Chart Being Loaded With Signals

Commentary (28 birž. 2024 @ 23:00):
Our systems believe the stock currently is overvalued by -0.03% compare to its pairs and should correct downwards.

Stats
Šios dienos apimtis	2.92M
Vidutinė apimtis	2.64M
Rinkos kapitalizacija	16.63B
EPS	$-0.790 ( Q1 \| 2024-05-03 )
Kita pelno data	( $0.110 ) 2024-08-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-12.81 (Sector) 42.63 (Industry) 0
ATR14	$3.65 (3.50%)

ACRS -0.90%

AKU -17.87%

APDN -0.73%

BDSX 2.00%

BIOC 0.00%

BNGO -7.69%

BNR 1.05%

CDNA 7.92%

CEMI 0.22%

CHEK -0.99%

CNTG -3.80%

CSTL 2.88%

DMTK -11.32%

DRIO 1.71%

EXAS -5.03%

FLDM -7.02%

FLGT -2.39%

GENE 1.35%

GH -0.59%

GTH 0.12%

HTGM 0.00%

ICLR 0.08%

IDXX -1.37%

ILMN -1.95%

ISPC -1.87%

LAB 0.00%

LMDX 0.00%

MDXH 0.84%

ME -7.58%

MEDP -2.94%

MYGN 0.62%

MYNZ -14.13%

NDRA -5.73%

NEO 3.97%

NEOG -2.07%

NOTV -4.05%

NTRA -1.56%

OCDX 0.92%

OLK 0.75%

OPGN 0.39%

OPK -0.79%

PMD 2.11%

PRPO 4.85%

PSNL -3.31%

RDNT 0.03%

SERA 3.50%

SHC -0.25%

SQL 0.00%

STIM -1.10%

STRR 2.71%

STRRP 8.67%

SYNH 0.02%

TRIB 2.90%

TTOO -1.66%

TWST 3.79%

VIVO 0.00%

XGN -1.62%

Insider Trading

Date	Person	Action	Amount	type
2024-06-10	Cunningham Everett	Buy	0	Common Stock
2024-06-10	Cunningham Everett	Buy	0	Common Stock
2024-06-10	Cunningham Everett	Buy	0	Common Stock
2024-06-10	Cunningham Everett	Buy	0	Common Stock
2024-05-16	Richo Anna	Buy	2 622	Common Stock

INSIDER POWER
83.84
Last 93 transactions
Buy: 263 719 \| Sell: 31 181

Koreliacija (AI algo v.1.1b): Overvalued: -0.03% $104.43 paired level. (Algoritmas realiuoju laiku stebi didžiausią koreliaciją turinčių akcijų pokyčius ir suteikia momentinę informaciją)

Tūris Koreliacija

Ilgas: -0.53 (weak negative)

Trumpas: 0.89 (strong)

Signal:(60) Same movement expected

Illumina Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
MBIO	0.894
APDN	0.878
SAGE	0.867
MPAA	0.865
JACK	0.865
VRSN	0.864
FAIL	0.864
INTZ	0.862
LSXMK	0.86
ASNS	0.86

10 Labiausiai neigiamai susiję koreliacijos
NKTR	-0.912
SMTC	-0.908
RVMD	-0.902
VERU	-0.901
AEYE	-0.9
USAP	-0.897
QRHC	-0.896
SGMA	-0.885
SLAM	-0.884
BNTC	-0.884

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Illumina Inc Koreliacija - Valiuta/Žaliavos

0.80
( moderate )

-0.09
( neutral )

0.00
( neutral )

-0.29
( neutral )

0.54
( weak )

-0.76
( moderate negative )

Illumina Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$4.50B
Bruto pelnas:	$2.75B (61.06 %)
EPS:	$-7.35

FY	2023
Pajamos:	$4.50B
Bruto pelnas:	$2.75B (61.06 %)
EPS:	$-7.35

FY	2022
Pajamos:	$4.58B
Bruto pelnas:	$2.97B (64.83 %)
EPS:	$-28.05

FY	2021
Pajamos:	$4.53B
Bruto pelnas:	$3.15B (69.69 %)
EPS:	$5.07

Financial Reports:

No articles found.

Illumina Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Illumina Inc

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.